Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis

Simple item page
dc.contributor.authorAki S.
dc.contributor.authorEskiyurt N.
dc.contributor.authorAkarirmak Ü.
dc.contributor.authorTüzün F.
dc.contributor.authorEryavuz M.
dc.contributor.authorAlper S.
dc.contributor.authorArpacioǧlu O.
dc.contributor.authorAtalay F.
dc.contributor.authorKavuncu V.
dc.contributor.authorKokino S.
dc.contributor.authorKuru Ö.
dc.contributor.authorNas K.
dc.contributor.authorÖzerbil Ö.
dc.contributor.authorSavaş G.
dc.contributor.authorSendur Ö.F.
dc.contributor.authorSoy D.
dc.contributor.authorAkyüz G.
dc.date.accessioned2024-07-22T08:24:44Z
dc.date.available2024-07-22T08:24:44Z
dc.date.issued2003
dc.description.abstractThe aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, nonplacebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 ± 8.6, with 51.2%in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).
dc.identifier.DOI-ID10.3349/ymj.2003.44.6.961
dc.identifier.issn05135796
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20090
dc.language.isoEnglish
dc.publisherYonsei University College of Medicine
dc.rightsAll Open Access; Gold Open Access
dc.subjectalendronic acid
dc.subjectantacid agent
dc.subjecthistamine H2 receptor antagonist
dc.subjectproton pump inhibitor
dc.subjectadult
dc.subjectaged
dc.subjectarthralgia
dc.subjectarticle
dc.subjectbone pain
dc.subjectcontrolled study
dc.subjectdigestive system function disorder
dc.subjectdose response
dc.subjectdrug absorption
dc.subjectdrug safety
dc.subjectepigastric pain
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmulticenter study
dc.subjectnausea
dc.subjectosteoporosis
dc.subjectpatient compliance
dc.subjectpatient information
dc.subjectretrospective study
dc.subjectretrosternal pain
dc.subjectskin manifestation
dc.subjectsymptomatology
dc.subjecttreatment withdrawal
dc.subjectTurkey (republic)
dc.subjectupper gastrointestinal tract
dc.titleGastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu